• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

二价新冠疫苗接种者对BQ.1.1、BN.1和XBB.1的中和活性：按既往感染类型和疫苗配方进行比较

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.

作者信息

Hyun Hak-Jun, Choi Min-Joo, Nham Eliel, Seong Hye, Yoon Jin-Gu, Noh Ji-Yun, Cheong Hee-Jin, Kim Woo-Joo, Yoon Sun-Kyung, Park Se-Jin, Gwak Won-Seok, Lee June-Woo, Kim Byoung-Guk, Song Joon-Young

机构信息

Department of Infectious Diseases, Ajou University School of Medicine, Suwon 16499, Republic of Korea.

Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon 22711, Republic of Korea.

出版信息

Vaccines (Basel). 2023 Aug 4;11(8):1320. doi: 10.3390/vaccines11081320.

DOI:10.3390/vaccines11081320
PMID:37631890
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10458764/
Abstract

Bivalent COVID-19 vaccines that contain BA.1 or BA.4/BA.5 have been introduced worldwide in response to pandemic waves of Omicron subvariants. This prospective cohort study was aimed to compare neutralizing antibodies (Nabs) against Omicron subvariants (BA.1, BA.5, BQ.1.1, BN.1, and XBB.1) before and 3-4 weeks after bivalent booster by the types of SARS-CoV-2 variants in prior infections and bivalent vaccine formulations. A total of 21 participants were included. Prior BA.1/BA.2-infected, and BA.5-infected participants showed significantly higher geometric mean titers of Nab compared to SARS-CoV-2-non-infected participants after bivalent booster (BA.1, 8156 vs. 4861 vs. 1636; BA.5, 6515 vs. 4861 vs. 915; BQ.1.1, 697 vs. 628 vs. 115; BN.1, 1402 vs. 1289 vs. 490; XBB.1, 434 vs. 355 vs. 144). When compared by bivalent vaccine formulations, Nab titers against studied subvariants after bivalent booster did not differ between BA.1 and BA.4/BA.5 bivalent vaccine (BA.1, 4886 vs. 5285; BA.5, 3320 vs. 4118; BQ.1.1, 311 vs. 572; BN.1, 1028 vs. 1095; XBB.1, 262 vs. 362). Both BA.1 and BA.4/BA.5 bivalent vaccines are immunogenic and provide enhanced neutralizing activities against Omicron subvariants. However, even after the bivalent booster, neutralizing activities against the later Omicron strains (BQ.1.1, BN.1, and XBB.1) would be insufficient to provide protection.

摘要

为应对奥密克戎亚变体的疫情浪潮，含有BA.1或BA.4/BA.5的二价新冠疫苗已在全球范围内投入使用。这项前瞻性队列研究旨在根据既往感染的新冠病毒变体类型和二价疫苗配方，比较二价加强免疫前和加强免疫3至4周后针对奥密克戎亚变体（BA.1、BA.5、BQ.1.1、BN.1和XBB.1）的中和抗体（Nab）。总共纳入了21名参与者。既往感染过BA.1/BA.2和BA.5的参与者在二价加强免疫后，其Nab几何平均滴度显著高于未感染新冠病毒的参与者（BA.1，8156对4861对1636；BA.5，6515对4861对915；BQ.1.1，697对628对115；BN.1，1402对1289对490；XBB.1，434对355对144）。按二价疫苗配方比较时，二价加强免疫后针对所研究亚变体的Nab滴度在BA.1和BA.4/BA.5二价疫苗之间没有差异（BA.1，4886对5285；BA.5，3320对4118；BQ.1.1，311对572；BN.1，1028对1095；XBB.1，262对362）。BA.1和BA.4/BA.5二价疫苗均具有免疫原性，并对奥密克戎亚变体提供增强的中和活性。然而，即使在二价加强免疫后，针对后期奥密克戎毒株（BQ.1.1、BN.1和XBB.1）的中和活性仍不足以提供保护。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/8aba397b9463/vaccines-11-01320-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/dc1de9fded0e/vaccines-11-01320-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/728761a14360/vaccines-11-01320-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/215191af01c3/vaccines-11-01320-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/8aba397b9463/vaccines-11-01320-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/dc1de9fded0e/vaccines-11-01320-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/728761a14360/vaccines-11-01320-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/215191af01c3/vaccines-11-01320-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/713c/10458764/8aba397b9463/vaccines-11-01320-g004.jpg

相似文献

1
Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.二价新冠疫苗接种者对BQ.1.1、BN.1和XBB.1的中和活性：按既往感染类型和疫苗配方进行比较
Vaccines (Basel). 2023 Aug 4;11(8):1320. doi: 10.3390/vaccines11081320.
2
Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.接种含BA.4/5的二价mRNA疫苗个体的血清对奥密克戎亚变体BN.1和XBB.1.5的中和活性较低。
Immune Netw. 2023 Nov 13;23(6):e43. doi: 10.4110/in.2023.23.e43. eCollection 2023 Dec.
3
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.比较携带早期和晚期 SARS-CoV-2 变异株刺突的单价和双价腺病毒疫苗的免疫原性。
Emerg Microbes Infect. 2024 Dec;13(1):2387447. doi: 10.1080/22221751.2024.2387447. Epub 2024 Aug 19.
4
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.第四剂二价 COVID-19 疫苗在诱导对奥密克戎亚变种的交叉反应性记忆 B 细胞方面优于单价加强针。
J Infect. 2024 Oct;89(4):106246. doi: 10.1016/j.jinf.2024.106246. Epub 2024 Aug 8.
5
Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.增强对奥密克戎亚谱系的中和作用：二价和单价 COVID-19 加强疫苗以及最近 SARS-CoV-2 奥密克戎变异株感染的相关见解。
Influenza Other Respir Viruses. 2024 Oct;18(10):e70000. doi: 10.1111/irv.70000.
6
COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2.孕期接种新冠病毒二价加强疫苗：母体和新生儿对奥密克戎BA.5、BQ.1、BF.7和XBB.1.5型严重急性呼吸综合征冠状病毒2的抗体反应
Vaccines (Basel). 2023 Aug 28;11(9):1425. doi: 10.3390/vaccines11091425.
7
Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.二价 COVID-19 疫苗接种后对疫苗株和奥密克戎亚变种（BQ.1.1、BN.1、XBB.1 和 EG.5）的长期体液和细胞免疫。
Front Immunol. 2024 May 2;15:1385135. doi: 10.3389/fimmu.2024.1385135. eCollection 2024.
8
Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.ChAdOx1-S疫苗接种和BA.4/5二价加强针后老年人群中SARS-CoV-2奥密克戎亚变体XBB.1.5、XBB.1.16和EG.5.1的免疫逃逸情况
Vaccines (Basel). 2024 Jan 30;12(2):144. doi: 10.3390/vaccines12020144.
9
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.原始mRNA疫苗或BA.5二价加强针 对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.
10
Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.奥密克戎变异株在坦桑尼亚流行期间评估 COVID-19 基础免疫系列接种后的交叉中和免疫反应。
J Med Virol. 2024 Aug;96(8):e29822. doi: 10.1002/jmv.29822.

引用本文的文献

1
Impact of imported COVID-19 cases on South Korea's response: variant transitions and regional patterns (2020-2023).输入性新冠病例对韩国应对措施的影响：变异株演变与区域模式（2020 - 2023年）
BMC Infect Dis. 2025 Jul 1;25(1):820. doi: 10.1186/s12879-025-11260-3.
2
Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination.二价mRNA新冠加强疫苗接种后，不同CD4水平的HIV感染者的免疫原性差异。
PLoS One. 2025 Apr 29;20(4):e0317940. doi: 10.1371/journal.pone.0317940. eCollection 2025.
3
Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico.

本文引用的文献

1
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.严重急性呼吸综合征冠状病毒2型奥密克戎XBB.1.16变体的病毒学特征
Lancet Infect Dis. 2023 Jun;23(6):655-656. doi: 10.1016/S1473-3099(23)00278-5. Epub 2023 May 3.
2
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.二价 mRNA 疫苗加强针预防 COVID-19 重症结局的有效性：一项回顾性队列研究。
Lancet Infect Dis. 2023 Aug;23(8):914-921. doi: 10.1016/S1473-3099(23)00122-6. Epub 2023 Apr 14.
3
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.
波多黎各SARS-CoV-2 IgG抗体持久性的纵向分析。
Sci Rep. 2024 Dec 28;14(1):30743. doi: 10.1038/s41598-024-80465-4.
4
Requirement of the N-terminal region of nonstructural protein 1 in cis for SARS-CoV-2 defective RNA replication.非结构蛋白 1 N 端区域在 SARS-CoV-2 缺陷型 RNA 复制中的顺式需求。
J Virol. 2024 Sep 17;98(9):e0090024. doi: 10.1128/jvi.00900-24. Epub 2024 Aug 28.
5
Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea.韩国12至17岁青少年中单价和二价mRNA新冠病毒加强疫苗的比较安全性
Osong Public Health Res Perspect. 2024 Aug;15(4):364-374. doi: 10.24171/j.phrp.2024.0081. Epub 2024 Jul 9.
二价与单价加强针后的新型冠状病毒2中和抗体
Lancet Infect Dis. 2023 May;23(5):527-528. doi: 10.1016/S1473-3099(23)00181-0. Epub 2023 Mar 29.
4
Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.同源和异源加强免疫在 Ad26.COV2.S 初免个体中的体液和细胞免疫原性：突破性感染的比较。
Front Immunol. 2023 Mar 7;14:1131229. doi: 10.3389/fimmu.2023.1131229. eCollection 2023.
5
Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study.新冠病毒变异株流行期间接受 COVID-19 疫苗接种的患者在预防严重疾病和死亡方面的效果：一项 K-COVE 研究。
J Korean Med Sci. 2023 Mar 20;38(11):e87. doi: 10.3346/jkms.2023.38.e87.
6
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.抗病毒药物和二价mRNA疫苗对SARS-CoV-2毒株CH.1.1的疗效
Lancet Infect Dis. 2023 May;23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. Epub 2023 Mar 7.
7
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.COVID-19 疫苗对成年人感染、住院和死亡的长期有效性：截至 2022 年 12 月快速实时系统证据综合和荟萃分析的结果。
Lancet Respir Med. 2023 May;11(5):439-452. doi: 10.1016/S2213-2600(23)00015-2. Epub 2023 Feb 10.
8
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.XBB.1.5增强传播性中的ACE2结合与抗体逃逸
Lancet Infect Dis. 2023 Mar;23(3):278-280. doi: 10.1016/S1473-3099(23)00010-5. Epub 2023 Feb 3.
9
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎XBB.1.5变体的传播性、感染性和免疫抗性增强。
Lancet Infect Dis. 2023 Mar;23(3):280-281. doi: 10.1016/S1473-3099(23)00051-8. Epub 2023 Jan 31.
10
Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.用二价疫苗中和BA.4-BA.5、BA.4.6、BA.2.75.2、BQ.1.1和XBB.1
N Engl J Med. 2023 Mar 2;388(9):854-857. doi: 10.1056/NEJMc2214916. Epub 2023 Jan 25.